LS9

What LS9 does

LS9 is a South San Francisco-based synthetic biology company founded in 2005 that engineers microorganisms to produce UltraClean™ renewable fuels and sustainable chemicals directly from renewable feedstocks. The company applies metabolic pathway engineering — a discipline co-founded by scientific founders George Church and Chris Somerville — to design microbial catalysts that convert sugars or other biomass into hydrocarbon-based products intended to be drop-in replacements for petroleum-derived fuels and chemical intermediates.

The company has raised approximately $78 million in venture capital across five funding rounds from 2007 to 2010, with BlackRock, Chevron Technology Ventures, Flagship Pioneering, Khosla Ventures, and Lightspeed Venture Partners among its investors. Chevron's role as a strategic investor suggests an intended downstream channel into petroleum refining and distribution; however, no commercial revenue, customer agreements, or post-2010 funding events are documented in the available data.

LS9 operates with a headcount in the 51–100 range, consistent with a pilot-stage industrial biotechnology platform rather than a fully commercial enterprise. Its business model is therefore best characterized as a pre-commercial licensing or partnership-driven approach, in which the value of the engineered microbial strains and associated intellectual property is monetized through partnerships with strategic off-takers in the fuels and chemicals value chain.

Name

LS9

Legal name

能名网 (Nengming.com)

Website

https://ls9.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Core offering

LS9 develops UltraClean™ renewable fuels and sustainable chemicals using proprietary synthetic biology. The company engineers microorganisms that convert renewable plant-based feedstocks into hydrocarbon molecules that are molecularly identical to petroleum-derived products, enabling drop-in replacement into existing fuel and chemical supply chains. The offerings target industrial buyers in the fuels, petrochemical, and chemicals markets.

Differentiator

Problem solved

Functional benefit

Products and services

• UltraClean™ Renewable Fuels
• Sustainable Chemicals

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Amyris: Synthetic-biology company engineering yeast to ferment sugars into hydrocarbon fuels and specialty chemicals. Most direct peer to LS9 in synbio route, drop-in hydrocarbon product line, and target renewable-diesel/SAF markets.
• LanzaTech: Gas-fermentation platform using engineered acetogens to convert industrial off-gases into ethanol and jet-fuel precursors. Comparable to LS9 as a microbe-catalyzed route to drop-in fuels and chemicals.
• Gevo: Developer of renewable gasoline, diesel, and sustainable aviation fuel (SAF) using both biological and catalytic routes. Targets the same drop-in fuel end markets as LS9 with overlapping SAF focus.
• Virent: Bio-based fuel and chemical company using catalytic chemistry to convert plant-based sugars into gasoline, diesel, and jet fuel. Direct overlap with LS9 in sugar-to-hydrocarbon fuel technology and end-product portfolio.
• Codexis: Engineered-enzyme and synthetic-biology company developing biocatalysts for pharmaceutical, food, and sustainable-fuel applications. Comparable to LS9 in synthetic-biology R&D platform serving fuels and chemicals.
• Zymergen: Synthetic-biology and automation platform company developing engineered microbial strains for specialty chemicals and materials. Comparable to LS9 as a synbio platform company targeting industrial chemicals markets.

Broad incumbents

• Renewable Energy Group (REG): Major U.S. renewable-diesel producer using the conventional hydrotreating/esterification pathway. Operates at commercial scale in the same end markets LS9 targets and historically partnered with LS9's strategic backers.
• Neste: Global leader in renewable diesel and SAF via the NEXBTL HVO/HEFA process. Represents the dominant incumbent pathway against which fermentation-based competitors like LS9 must compete.
• Synthetic Genomics: Synthetic-biology company developing engineered algae and microbes for biofuels and biochemicals. Overlaps with LS9 in synthetic-biology platform, hydrocarbon target molecules, and fuels focus.

Others

• TeselaGen: Synthetic-biology software and data platform serving bio-fuel and industrial-biotech developers. Adjacent enabling technology for synbio-fuel companies like LS9 rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LS9